Did Raptiva cause your brain infection?
1-866-735-2792
Start Here

Fill out this brief form to find out if you have a Raptiva Lawsuit:
First Name:
Last Name:
E-mail:
Address:
City:
State:
Zipcode:
Phone:
() -
 
Have any of the following symptoms or injuries occured:
Brain Infection
Loss of Vision
PML
Death 		Problems Walking
Speech Problems
Other Serious Infections
Dates Raptiva injections were received:
Start Date:
End Date:
Are you still receiving injections?
Yes No
Please describe any side effects:
Other comments / questions:

FDA Updates Raptiva Box Warning Label to
"Serious Infection Risk"

Raptiva Medicine

In October 2008, the Food and Drug Administration announced labeling changes, including a Boxed Warning for the psoriasis drug Raptiva.

The now-required Raptiva Boxed Warning will highlight the risk of bacterial sepsis, viral meningitis, invasive fungal disease, PML (progressive multifocal leukoencephalopathy), and other opportunistic infections.

Contact Our Raptiva Lawyers Today »

"The monitoring arm of the FDA has received reports of serious infections leading to hospitalizations and deaths for patients using Raptiva."

Raptiva works by suppressing the immune system to reduce psoriasis flare-ups. However, by suppressing the body's natural defense system, it can also increase the risk of serious infections and malignancies in patients.

The Boxed Warning labeling changes are based on the FDA's post-market surveillance. The FDA is also requiring the submission of a Risk Evaluation and Mitigation Strategy (REMS), which will include a Medication Guide for patients and a timetable for assessment of the REMS.

The monitoring arm of the FDA has received reports of serious infections leading to hospitalizations and deaths for patients using Raptiva. The FDA received reports of serious infections in some patients taking Raptiva. These reports led to their decision to highlight the risks in the drugs labeling. Doctors and other prescribers should carefully evaluate and weigh the risk/benefit profile of Raptiva for patients who would be more susceptible to these risks.

The updated label also includes a warning about certain neurologic events as well as precautions regarding immunizations and pediatric use. A Dear Healthcare Provider letter was issued to communicate this updated prescribing information to healthcare professionals.

Do You Have a Raptiva Psoriasis Drug Lawsuit? »

Raptiva's label will be updated to include data from juvenile animal studies in mice indicating a potential risk for the permanent suppression of the immune system with repeat administration of Raptiva. The psoriasis drug is not approved for children younger than 18 years of age.